A Capillary THC Study Obtained Acceptable Samples in 77% of Collection Attempts

A capillary cannabinoid study obtained acceptable specimens in 148 of 192 collection attempts, or 77%. That collection-success denominator matters alongside the chemical assay’s accuracy: a convenient device cannot provide a usable result when collection fails.

Which collection method was actually evaluated?

Twenty-nine adults used their own cannabis products under a naturalistic inhalation protocol. Researchers collected capillary blood from the upper outer arm with a microneedle device and paired it with forearm venous blood before and after use.

The study ultimately supplied 144 matched capillary–venous pairs. Repeated samples from the same people allowed time-course comparisons, but they did not constitute 144 independently exposed participants.

Failure occurred for several practical reasons

Reported failures involved insufficient volume, failure of the device to adhere, lack of skin puncture and clotting. Samples containing less than 50 microliters were rejected from analysis.

These failures describe the device and procedures used in this study. They do not establish a failure rate for every capillary device, collection site or operator. They nevertheless identify a practical limitation that concentration comparisons alone would miss.

The research workflow differed from standard handling

To address clotting and align storage conditions, researchers transferred collected capillary blood into glass vials containing the same preservative types used for venous specimens. They also used measures intended to improve blood flow.

The authors stated that results might differ if capillary samples remained in the original collection containers with their supplied anticoagulant. Thus, the validated comparison should not be attributed automatically to every unmodified implementation of the device.

Collection success and matrix agreement remain separate

Among usable paired specimens, parent THC was generally lower in capillary than venous blood after inhalation. Some differences were statistically significant, while later comparisons in some groups were not. Metabolites showed a different pattern.

For an actual result, establish the collection site, obtained volume, container transfer, preservatives and timing. Neither successful collection nor a correlation between paired concentrations independently establishes impairment. This study’s practical contribution is showing that specimen availability, specimen comparability and functional interpretation each require separate evidence.

Related: Interpreting THC concentration and impairment.

Primary research

Comparison of Δ9-tetrahydrocannabinol in venous and capillary blood following ad libitum cannabis smoking by occasional and daily users. DOI: 10.1093/jat/bkaf043.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

CBD Epilepsy Trial Liver-Enzyme Events Often Involved Concomitant Valproate

Liver-enzyme events during CBD epilepsy trials often occurred in patients also taking valproate. That pattern makes the full medication regimen important, but it does not isolate which drug caused an individual event or establish safety without valproate. The finding came from treated epilepsy populations An original reanalysis of four randomized…

Spread the love

Read Article: CBD Epilepsy Trial Liver-Enzyme Events Often Involved Concomitant Valproate

Serum Cannabinoid Fingerprints Did Not Reliably Separate Medical and Street Cannabis

A broad serum cannabinoid panel did not reliably distinguish THC-rich medical cannabis from street cannabis in a pilot study. More analytes supplied useful patterns, but they did not create a universal test for prescription-source attribution. Different products were represented The study recruited 23 patients receiving cannabis-based medicines or medical cannabis…

Spread the love

Read Article: Serum Cannabinoid Fingerprints Did Not Reliably Separate Medical and Street Cannabis

Stored Cannabinoid Urine Screens Lost Signal Without Measuring Chemical Degradation

A stored urine specimen can lose cannabinoid screening response, but the response alone does not reveal exactly how much of a named compound chemically degraded. An analog-stability study used immunoassay signal as its endpoint rather than compound-specific mass-spectrometric concentrations. The experiment used fortified human urine Researchers added individual cannabinoid analogs…

Spread the love

Read Article: Stored Cannabinoid Urine Screens Lost Signal Without Measuring Chemical Degradation

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us